

Microtubule Stability," J. Med. Chem. 2000 Jun 15, 43(12):2419-2429.

### Methods and Compositions for Transforming Dendritic Cells and Activating T Cells

Patrick Hwu *et al.* (NCI).

U.S. Patent No. 6,734,014

Issued 11 May 2004

(DHHS Reference No. E-040-1996/0-US-07).

*Licensing Contact:* Jeff Walenta; 301/435-4633; [walenta@mail.nih.gov](mailto:walenta@mail.nih.gov).

T cells mediate most forms of cellular immunity. Typically T cells do not respond to free antigenic peptides, but instead T cells interact with a specialized set of cell surface proteins, which are the class I and class II major histocompatibility complexes, or MHC. Specialized antigen-presenting cells, such as macrophage and dendritic cells, present antigenic peptides on the surface cells in conjunction with the MHC molecules, and induce cytotoxic T cells to proliferate. T cells are induced by these antigen-presenting cells to recognize corresponding antigens expressed on MHC antigens on the surface of target cells, and destroy these target cells.

This invention describes a novel method for making transformed dendritic cells with any recombinant nucleic acid, which have been difficult to transduce using existing methods. Recombinant dendritic cells are made by transforming a stem cell and differentiating the stem cell into a dendritic cell. The resulting dendritic cell is an antigen-presenting cell that activates T cells against MHC class I-antigen targets. The present invention provides a valuable tool for the treatment of cancer, and viral and parasitic infections using the recombinant dendritic cells. The invention also provides therapeutic compositions and pharmaceutical compositions.

This research is described in Reeves *et al.*, "Retroviral Transduction of Human Dendritic Cells with a Tumor-Associated Antigen Gene," Cancer Res. 1996 Dec 15, 56(24):5672-5677.

Dated: August 18, 2004.

**Steven M. Ferguson,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. 04-19539 Filed 8-25-04; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Clinical Center; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the NIH Advisory Board for Clinical Research.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

*Name of Committee:* NIH Advisory Board for Clinical Research.

*Date:* September 21, 2004.

*Time:* 2 p.m. to 6 p.m.

*Agenda:* For discussion of planning, operational, and clinical research issues.

*Place:* National Institutes of Health, Building 1, 1 Center Drive, Room 151, Bethesda, MD 20892.

*Contact Person:* Maureen E. Gormley, Executive Secretary, Warren Grant Magnuson Clinical Center, National Institutes of Health, Building 10, Room 2C146, Bethesda, MD 20892, 301/496-2897.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Dated: August 19, 2004.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 04-19548 Filed 8-25-04; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Fogarty International Center; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Fogarty International Center Advisory Board.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Fogarty International Center Advisory Board.

*Date:* September 14, 2004.

*Open:* 8:30 a.m. to 12 p.m.

*Agenda:* A Report of the FIC Director on updates and overviews of new FIC initiatives. The main topics of the Board will be "U.S. Attitudes Toward International Efforts."

*Place:* National Institutes of Health, Lawton Chiles International House, Bethesda, MD 20892.

*Closed:* 1 p.m. to Adjournment.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Lawton Chiles International House, Bethesda, MD 20892.

*Contact Person:* Jean L. Flagg-Newton, Special Assistant to the Director, FIC.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute's/Center's home page: <http://www.nih.gov/fic/about/advisory.html>, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.106, Minority International Research Training Grant in the Biomedical and Behavioral Sciences; 93.154, Special International Postdoctoral Research Program in Acquired Immunodeficiency Syndrome; 93.168, International Cooperative Biodiversity Groups Program; 93.934, Fogarty International Research Collaboration Award; 93.989, Senior International Fellowship Awards Program, National Institutes of Health, HHS)

Dated: August 19, 2004.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 04-19547 Filed 8-25-04; 8:45 am]

**BILLING CODE 4140-01-M**